Abstract 266P
Background
Combination of chemotherapy plus immune checkpoint inhibitors (ICIs) has recently shown efficacy in triple-negative breast cancer (TNBC), and thus, has been introduced in clinical practice in both the advanced and early disease stage. However, few data are available regarding the extent and the potential consequences of discontinuation rate and serious adverse events of these treatments, especially in the neoadjuvant setting. Herein, we performed a comprehensive systematic review and meta-analysis to assess discontinuation rate and serious adverse events of chemoimmunotherapy compared to chemotherapy alone in phase II and III neoadjuvant clinical trials in TNBC.
Methods
Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, EMBASE, Cochrane Library, and PubMed/ Medline were searched for articles published from June 2008 to March 2023. The outcomes of interest were discontinuation rate, serious adverse events, and grade 3-4 adverse events.
Results
Overall, 4 studies were included in the analysis. The pooled Odds Ratios (ORs) for discontinuation rate and serious adverse events were 1.26 (95% CI, 0.78-2.06) and 1.79 (95% CI, 1.4-2.28), respectively, in patients receiving chemoimmunotherapy versus chemotherapy alone as neoadjuvant treatment for TNBC. A higher risk of grade 3-4 adverse events was reported in the chemoimmunotherapy group (OR 1.30; 95% CI, 1.07-1.59). The analysis was associated with substantial heterogeneity and the risk of discontinuation rate was strongly conditioned by the KEYNOTE-522 trial.
Conclusions
Our findings support the design of clinical trials which could be specifically focused on safety and treatment adherence, as well as the potential impact on outcome and quality of life in TNBC patients receiving neoadjuvant treatment. Careful monitoring of tolerability remains a crucial need in this clinical setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Giuliano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02